Læknaneminn - 01.04.1996, Blaðsíða 50

lyfjameðferð gegn sýkingu af völdum alnæmisveiru - ný viðhorf
endanlegan árangur lyíjameðferðar gegn alnæm-
isveiru enda eru menn minnugir vonbrigða sem ný
lyf gegn sjúkdómnum hafa valdið á árum áður.
HEIMILDIR
1. Wei X et al. Viral dynamics in human immunodeficiency
virus type 1 infection. Nature 1995; 373: 117.
2. Ho DD et al. Rapid turnover of plasma virions and CD4
lymphocytes in HIV-1 infection. Nature 1995; 373: 123.
3. Volberding PA. HIV quantification. Lancet 1996; 347:
71.
4. Wain-Hobson S. Viral Burden in AIDS. Nature 1993;
366: 22.
5. Pantaleo G et al. HIV infection is active and progressive in
lymphoid tissue during the clinical latent stage of disease.
Nature 1993; 362: 355.
6. Embretson J et al. Massive covert infection of helper T
lymphocytes and macrophages by HIV during the incuba-
tion period of AIDS. Nature 1993; 362; 359.
7. Thomas RO et al. HIV- 1 RNA levels and time to AIDS.
3rd Conference on Retroviruses and Oportunistic Infect-
ions, Jan 28 - Feb 2, 1996, Washington, DC.
8. Mellors JW et al. Prognosis in HIV-1 infection predicted
by the quantity of virus in plasma. Science 1996; 272:
1167.
9. O’Brien WA et al. Changes in plasma HIV-1 RNA and
CD4+ lymphocyte counts and the risk of progression to
AIDS. N EnglJ Med 1966; 334: 426.
10. Current topics. Combinations, new drugs outperform
AZT. ASM News 1995; 61: 620.
11. Voelker R. New studies say viral burden tops CD4 as a
marker of HIV disease progression. JAMA 1996; 275:
421.
12. Stephenson J. New anti-HIV drugs and tratment strateg-
ies buoy AIDS research. JAMA 1996; 275: 579.
13. Ho DD. Time to hit HIV early and hard. N Engl J Med
1995; 333: 450.
14. Kinloch-de Loes et al. A controlled trial of zidovudine in
primary human immunodeficiency virus infection. N
Engl J Med 1995; 333: 408.
15. Guðmundsson S. Lyfjameðferð gegn alnæmisveiru.
Læknaneminn 1992; 45: 11.
16. Fischl MA et al. The efficacy of azidothymidine (AZT) in
treatment of patients with AIDS and AIDS related comp-
lex: a double blind, placebo controlled trial. N Engl J Med
1987; 317: 185.
17. Volberding PA et al. Zidovudine in asymptomatic human
immunodeficiency virus infection: a controlled trial in
persons with fewer than 500 CD4-positive cells per cubic
millimeter. N Engl J Med 1990; 322: 941.
18. Aboulker J-P, Swart AM. Preliminary analysis of the
Concorde trial. Lancet 1993; 341: 889
19. Volberding PA et al. A comparison of immediate with
deferred zidovudine therapy for asymptomatic HlV-in-
fected adults with CD4 cells count of 500 or more per
cubic millimeter. N Engl J Med 1995; 333: 410-7
20. Cooper DA et al. Zidovudine in persons with asymptom-
atic HIV infection and CD4 cell counts greater than 400
per cubic millimeter. N Engl J Med 1993; 329: 297
21. Kahn JO et al. A controlled trial comparing continued
zidovudine with didanosine in human immunodeficiency
virus infection, N Engl J Med 1992; 327: 581.
22. Abrams DI et al. A comparative trial of didanosine or
zalcitabine after treatment with zidovudine in patients
with human immunodeficiency virus infection. N Engl J
Med 1994; 330: 657
23. Fischl MA et al. Combination and monotherapy with
zidovudine and zalcitabine in patients with advanced HIV
disease. Ann Intern Med 1995; 122: 24
24. Pollard R et al. Antiviral effect and safely of stavudine
(d4T) and didanosine (ddl) combination therapy in HIV-
infected subjects in an ongoing pilot randomized double-
blinded Trial. 3rd Conference on Retroviruses and
Opportunistic Infections, Jan 28 - Feb 2, 1996, Was-
hington, DC.
25. Bartlett JA Long-term safety and efficacy of lamivudine
(LMV) plus zidovudine (ZDV) compared with zalcitabine
(ddC) plus ZDV in ZDV-experienced patients with
absolute CD4+ cells = 100-300/mm3.3rd Conference on
Retroviruses and Opportunistic Infections, Jan 28 - Feb 2,
1996, Washington, DC.
26. Eron B et al. Treatment with lamivudine, zidovudine, or
both in HlV-positive patients with 200 to 500 cd4+ cells
per cubic millimeter. N Engl J Med 1995; 333: 1662
27. Johnson VA et al. Drug resistance and viral load in NUCA
3002: lamivudine (3TC) (high or low dose)/zidovudine
(ZDV) combination therapy versus ZDV/dideoxycytidine
(ddC) combination therapy in ZDV-experienced (>=24
weeks) patients (CD4 cells 100-300/mm3). 3rd Confer-
ence on Retroviruses and Opportunistic Infections, Jan 28
- Feb 2, 1996, Washington, DC.
28. Pagano PJ et al. In vitro inhibition of human immunodef-
iciency virus type 1 by a combination of delavirdine (U-
901152) with protease inhibitor (U-75857). J Infect Dis
1995; 171:61.
29. Naiva M et al. Three dimensional structure of aspartyl
protease from human immunodeficiency virus HIV-1.
Nature 1989; 337: 615.
30. Rosé JR, Craik CS. Structure-assisted design of nonpetide
human immunodeficiency virus-1 protease inhibitors. Am
J Respir Crit Care Med 1994; 150: S176.
31. Cameron B et al. Prolongation of life and prevention of
LÆKNANEMINIM
44
1. tbl. 1996, 49. árg.